Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABA(A) Receptor

Recently, we developed the fatty acid-binding protein 3 (FABP3) ligand MF1 (4-(2-(1-(2-chlorophenyl)-5-phenyl-1H-pyrazol-3-yl)phenoxy) butanoic acid) as a therapeutic candidate for α-synucleinopathies. MF1 shows affinity towards γ-aminobutyric acid type-A (GABA(A)) receptor, but its effect on the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yabuki, Yasushi, Liu, Jiaqi, Kawahata, Ichiro, Izumi, Hisanao, Shinoda, Yasuharu, Koga, Kohei, Ueno, Shinya, Shioda, Norifumi, Fukunaga, Kohji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432285/
https://www.ncbi.nlm.nih.gov/pubmed/32752296
http://dx.doi.org/10.3390/ijms21155525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432285/
https://www.ncbi.nlm.nih.gov/pubmed/32752296
http://dx.doi.org/10.3390/ijms21155525

Ejemplares similares